Samsung Submits MAA for Remicade Biosimilar For Crohn’s Disease, Ulcerative Colitis to EMA

Samsung Submits MAA for Remicade Biosimilar For Crohn’s Disease, Ulcerative Colitis to EMA
Samsung Bioepis Co. Ltd. recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) regarding a biosimilar treatment for several conditions, including Crohn’s disease and ulcerative colitis. The Remicade (Infliximab) biosimilar candidate, called SB2, is now the second biosimilar candidate by Samsung Bioepis to file for an MAA from the EMA. Samsung filed the application based

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *